Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Authors
Keywords
-
Journal
BMC Medicine
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-22
DOI
10.1186/s12916-020-01610-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-VEGF drug interference with VEGF quantitation in the R&D systems human quantikine VEGF ELISA kit
- (2019) Giane Sumner et al. Bioanalysis
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
- (2019) Ulrich Herrlinger et al. LANCET
- Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma
- (2019) Elizabeth Gerstner et al. CLINICAL CANCER RESEARCH
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
- (2019) Quinn T Ostrom et al. NEURO-ONCOLOGY
- Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
- (2018) J. N. Jakobsen et al. JOURNAL OF NEURO-ONCOLOGY
- Current Challenges and Opportunities in Treating Glioblastoma
- (2018) Andrea Shergalis et al. PHARMACOLOGICAL REVIEWS
- Serum VEGF-A concentrations in patients with central nervous system (CNS) tumors
- (2018) Agnieszka Nowacka et al. PLoS One
- Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab
- (2018) Pradeep Goyal et al. QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
- (2017) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Optimizing bevacizumab dosing in glioblastoma: less is more
- (2017) Abdulrazag Ajlan et al. JOURNAL OF NEURO-ONCOLOGY
- Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma
- (2017) Kartik Angara et al. Translational Oncology
- Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
- (2017) Mogens K. Boisen et al. Oncotarget
- Prognostic significance of vascular endothelial growth factor polymorphisms in colorectal cancer patients
- (2017) Gilmar Ferreira do Espírito Santo et al. World Journal of Gastrointestinal Oncology
- Lessons Learned from the Bevacizumab Experience
- (2017) Joanne Mortimer et al. Cancer Control
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
- (2016) Michele Ceccarelli et al. CELL
- Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after in vitro passaging in serum-free media
- (2016) Noemí García-Romero et al. Oncotarget
- Effects of endothelial cell proliferation and migration rates in a computational model of sprouting angiogenesis
- (2016) Kerri-Ann Norton et al. Scientific Reports
- Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial
- (2015) Thomas Sandmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
- (2015) C. Zahonero et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy and safety of bevacizumab for the treatment of glioblastoma
- (2015) ZHIYUN YU et al. Experimental and Therapeutic Medicine
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-Angiogenic Therapy in High-Grade Glioma (Treatment and Toxicity)
- (2013) Jennie Taylor et al. Current Treatment Options in Neurology
- VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level
- (2013) T. Arcondeguy et al. NUCLEIC ACIDS RESEARCH
- Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
- (2013) Gazanfar Rahmathulla et al. OncoTargets and Therapy
- Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease
- (2013) S. Goel et al. Cold Spring Harbor Perspectives in Medicine
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
- (2012) Petra Hamerlik et al. JOURNAL OF EXPERIMENTAL MEDICINE
- AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
- (2011) O. L. Chinot et al. ADVANCES IN THERAPY
- Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept
- (2011) J. F. de Groot et al. CLINICAL CANCER RESEARCH
- Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells
- (2011) L. von Baumgarten et al. CLINICAL CANCER RESEARCH
- Vascular Endothelial Growth Factor A (VEGF-A) Induces Endothelial and Cancer Cell Migration through Direct Binding to Integrin α9β1
- (2010) Saji Oommen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The VEGF family in cancer and antibody-based strategies for their inhibition
- (2010) Laura A. Sullivan et al. mAbs
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiogenesis as a Therapeutic Target in Malignant Gliomas
- (2009) A. S. Chi et al. ONCOLOGIST
- Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
- (2008) Sith Sathornsumetee et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started